RxDoctor Payments Data

Kamran Qureshi, MD

Internal Medicine · Hemet, CANPI 1326156472

Payments from drug & device makers

$3,680in general payments, 2019–2025

Across 74 payments — averaging $49.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Lilly USA, LLC$129
  • Abbott$117
  • Phathom Pharmaceuticals, Inc.$81
  • Merck$78
  • GSK$74
  • plus $948 from 23 others

What the payments were for

  • Consulting fees$2,14858%
  • Food & beverage$1,53242%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,680 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$86,093
Medicare patients
228
Services billed
746

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban136$103,215
OzempicSemaglutide71$74,016
JardianceEmpagliflozin60$54,757
JanuviaSitagliptin Phosphate48$49,598
XareltoRivaroxaban22$28,138
RybelsusSemaglutide20$27,283
MyrbetriqMirabegron22$22,735
FarxigaDapagliflozin Propanediol17$17,327
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$15,858
Incruse ElliptaUmeclidinium Bromide24$14,735
EntrestoSacubitril/Valsartan15$12,741
BrilintaTicagrelor13$12,031
Humalog Kwikpen U-200Insulin Lispro13$11,219
Lantus SolostarInsulin Glargine,hum.Rec.Anlog104$9,725
Albuterol Sulfate HfaAlbuterol Sulfate210$9,559

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$55$108,308147 claims
Novo NordiskOzempic, Rybelsus$64$101,29991 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat, Tradjenta$43$81,20999 claims
MerckJanuvia, Janumet, Belsomra$78$63,45272 claims
GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta$74$37,68852 claims
AstraZenecaFarxiga, Brilinta$2,254$29,35830 claims
Johnson & JohnsonXarelto$20$28,13822 claims
NovartisEntresto$47$12,74115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Hemet

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →